Title: Bring it home, Inside the movement to put generic drug production back on America's shores

Without the coronavirus pandemic, it’s possible that the impact of Rosemary Gibson’s work would have mostly been felt inside the policy and industry circles of pharma. But in the topsy-turvy world of COVID-19, experts have suddenly been propelled to a new kind of notoriety as they’ve been called upon regularly to explain the various issues in our health care system — Gibson among them. Since publishing her book, “China RX: Exposing the Risks of America’s Dependence on China for Medicine,” in 2018, Gibson has been kicking up a storm about our over-reliance on drug imports — particularly active pharmaceutical ingredients (APIs) for generic drugs. And evidence of our vulnerability to China’s control of the drug supply was on display even before the coronavirus. In 2018, a massive recall of blood pressure medications swept through the industry, triggered by tainted APIs from China. By the end of 2019, the push to improve the quality and security of America’s global supply chain was gaining bipartisan steam in Congress.

Click Here For Complete Article Text


   Person Information
   Application Sequencing
 325412 - Pharmaceutical Preparation Manufacturing                
Company  Product  Process  Other  Subjects  Event  Event  Date  Location  Publication  Publication  Date Text  Descriptor

  • Manufacturing





  • Pharma Manufacturing


  • 9/16/2020


  • Article